SGLT2 inhibitors reduce HbA1c, but their cardiovascular and renal benefits (reduced MACE, hospitalisation for heart failure, and CKD progression) appear to be partly independent of glycaemic control. The primary mechanism underlying their cardiorenal benefit is:
- A Reduction in postprandial glucose preventing oxidative endothelial damage
- B Restoration of tubuloglomerular feedback by reducing proximal tubular sodium/glucose reabsorption, combined with natriuresis and erythropoiesis stimulation ✓
- C Glucosuria-induced caloric deficit causing weight loss and blood pressure reduction
- D Selective activation of PPAR-gamma receptors in cardiomyocytes improving substrate utilization
Explanation
SGLT2 inhibitors inhibit the SGLT2 cotransporter in the S1 segment of proximal tubule, reducing glucose and sodium co-transport. The increased sodium delivery to the macula densa restores tubuloglomerular feedback, reducing single-nephron hyperfiltration (protecting against DKD). Natriuresis reduces preload. Mild erythrocytosis from raised EPO (due to renal signalling) improves cardiac oxygenation. Additionally, a shift toward ketone body utilization ('thrifty substrate' hypothesis) may improve cardiac energy metabolism. These mechanisms together explain outcome benefits beyond glycaemic effects.
Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.